Counsel the parents of a child with a first demyelinating event — OSCE

Candidate brief and communication tasks

The candidate enters the room to find the parents anxious and holding a phone showing a multiple-sclerosis webpage. The task is to counsel them over eight minutes: explain what has happened to their son in plain language, justify the immediate treatment, outline the antibody-led workup, set realistic expectations about recovery and the long-term outlook, and address the multiple-sclerosis worry without false reassurance. The communication skill is to convey urgency without alarm and to share the decision-making honestly while the diagnosis is still resolving. [1]

The first task is to name the event in plain language. The candidate explains that their son's immune system, instead of clearing the recent cold, has mistakenly attacked the protective coating of the nerves in his brain - a first demyelinating event called acute disseminated encephalomyelitis, or ADEM. The candidate links the bedside picture - drowsiness, irritability, the weak side, the slurred speech - to the widespread inflammation on the scan, and explains that this is why he is drowsy: the inflammation is disrupting how the nerves conduct, and the treatment is to calm that inflammation quickly. [1]

The second task is to justify the immediate treatment and set the recovery expectation. The candidate explains that the team has started high-dose steroid medicine through a drip - the standard first treatment for this kind of inflammation - and that most children with ADEM recover well over the coming weeks, though recovery is gradual and rehabilitation will help. The candidate is honest that the team will watch the response over the first two to three days and, if the inflammation is not settling, will add other immune treatments such as immunoglobulin or a blood-cleaning procedure called plasma exchange. [2]

The third task is to address the multiple-sclerosis worry and the antibody workup. The candidate acknowledges what the parents have read, and explains that ADEM is a different disorder from multiple sclerosis in most children, but that the team is sending specific blood tests - antibody tests - to be certain, because there are four related disorders in this family and the long-term treatment depends on getting that answer right. The candidate explains that the team will not start any long-term medicine until those antibody results are back - in particular, that a multiple-sclerosis medicine would not be used unless the tests confirm multiple sclerosis - and that the answer will be available within a few weeks. [1] [3]

The fourth task is to share the decision-making and close the loop. The candidate invites the parents' questions, checks their understanding, agrees on a plan for the next forty-eight hours (the steroid response, the escalation plan, the rehabilitation referral), and arranges a follow-up conversation once the antibody results return. The candidate closes by affirming that the immediate priority is calming the inflammation and supporting recovery, that the team will share the antibody results and their meaning as soon as they are available, and that a named doctor and nurse will be the family's point of contact throughout. [2] [3]

Examiner discussion points

After the encounter, the examiner probes the candidate's clinical reasoning. Why is encephalopathy the defining feature of ADEM, and how does it separate this child from a clinically isolated syndrome? The candidate answers that encephalopathy is the mandatory discriminator under the IPMSSG definitions. Why must a multiple-sclerosis drug not be started before the antibody status is known? The candidate explains the biological mismatch and the risk of worsening aquaporin-4-positive neuromyelitis optica spectrum disorder. What is the escalation if the child is steroid-refractory at forty-eight to seventy-two hours? The candidate answers intravenous immunoglobulin or plasma exchange. The examiner closes by affirming the communication principle: convey urgency without alarm, share the decision-making honestly, and hold the long-term label until the antibody answer resolves it. [1] [3]